AstraZeneca

AZNleader

AstraZeneca is a global biopharmaceutical company with a market-leading oncology portfolio and strong positions in cardiovascular, respiratory, and rare disease therapies.

⇄ Compare

Products & Revenue

Product Revenue Share

Revenue Breakdown ($49.8B)

Static data (loading live financials…)

Oncology (40%)

BioPharmaceuticals (38%)

Rare Disease (Alexion) (17%)

Other (5%)

Segment Breakdown & Key Customers

Product Details

Oncology Portfolio40%

Tagrisso, Imfinzi, Enhertu, and Lynparza cancer treatments

Cardiovascular/Renal/Metabolic22%

Farxiga, Brilinta, and Lokelma for heart and kidney disease

Respiratory & Immunology20%

Symbicort, Fasenra, and Tezspire for asthma and COPD

Rare Disease (Alexion)18%

Soliris, Ultomiris for complement-mediated diseases

Supply Chain Relationships

Competitors

Merck & Co.

Oncology immunotherapy

Impact: High — PD-L1 vs PD-1 competition

Pfizer Inc.

Respiratory and oncology

Impact: Medium — multiple overlapping areas

Partners

Eli Lilly and Company

Enhertu co-development (with Daiichi Sankyo)

Impact: N/A — Daiichi partner, Lilly rival

Macro & Market Context

제약 / 바이오Sector News

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Upcoming Catalysts

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Latest News

Loading news...

AI Analysis

Click "Get AI Analysis" for an AI-powered supply chain analysis of AstraZeneca.

Company Info

Headquarters

Cambridge, United Kingdom

Founded

1999

Employees

89,000+

Website

astrazeneca.com

Sector Overview — 제약 / 바이오

Sector News